BioStock: Lipum seeks patent protecting inflammation-driven cancer treatment
Lipum has submitted an international patent application for SOL-116 as a treatment for inflammation-driven cancer. The patent application is based on the company’s research demonstrating that SOL-116 inhibits the growth of cancer cells by blocking the target protein BSSL. Additionally, studies on breast cancer patients indicate that high expression of BSSL correlates with a poor prognosis and shorter survival.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/lipum-seeks-patent-protecting-inflammation-driven-cancer-treatment/ This is